14676 results for "PLOS+ONE+Pennsylvania+German+ACS+language+code+pdc+open+access+study"

in 17.00 milliseconds.

• Reference epigenome SMC08_WGBS data generated from KEP study

  A SMC08_WGBS paired end data for skeletal muscle cells

  Dataset EGAD00001003876

• Reference epigenome SMC09_WGBS data generated from KEP study

  A SMC09_WGBS paired end data for skeletal muscle cells

  Dataset EGAD00001003877

• Reference epigenome Pancreas-Islet08 miRNA-Seq data generated from KEP study

  Pancreas-Islet08 miRNA-Seq single end data

  Dataset EGAD00001007189

• Reference epigenome CKD23_C_Mesan_mRNA-Seq data generated from KEP study

  A CKD23_C_Mesan_mRNA-Seq paired end data for Mesangial cells(kidney)

  Dataset EGAD00001003481

• Reference epigenome Islet-derived_iPSC04 mRNA-Seq data generated from KEP study

  Islet-derived_iPSC04 mRNA-Seq paired end data

  Dataset EGAD00001007880

• Reference epigenome Islet-derived_MSC08 mRNA-Seq data generated from KEP study

  Islet-derived_MSC08 mRNA-Seq paired end data

  Dataset EGAD00001007879

• Reference epigenome Islet-derived_MSC06 miRNA-Seq data generated from KEP study

  Islet-derived_MSC06 miRNA-Seq single end data

  Dataset EGAD00001007881

• Reference epigenome SMC01_WGBS data generated from KEP study

  A SMC01_WGBS paired end data for skeletal muscle cells

  Dataset EGAD00001003871

• Reference epigenome KNIH011 miRNA-seq data generated from KEP study

  A KNIH011 miRNA-seq single end data for podocytes

  Dataset EGAD00001002770

• Reference epigenome KNIH011 mRNA-seq data generated from KEP study

  A KNIH011 mRNA-seq paired end data for podocytes

  Dataset EGAD00001002177

• Reference epigenome KNIH010 mRNA-seq data generated from KEP study

  A KNIH010 mRNA-seq paired end data for podocytes

  Dataset EGAD00001002176

• Reference epigenome CKD27_C_Mesan_mRNA-Seq data generated from KEP study

  A CKD27_C_Mesan_mRNA-Seq paired end data for Mesangial cells(kidney)

  Dataset EGAD00001003484

• Validation_for_human_early_embryonic_substitutions_

  PCR and MiSeq validation for early embryonic substitution candidates from 400 Breast cancer patients

  Study EGAS00001001218

• Low_input_LC__WGS_

  R&D project to develop low input library construction methods.

  Study EGAS00001001855

• Exploring_the_landscape_of_somatic_mutations_in_normal_tissue___POL___TGS_

  Somatic mutations (burdens and signatures) and clonal dynamics in individuals with germline DNA polymerase mutations.

  Study EGAS00001003754

• Genomics of drug sensitivity in acute lymphoblastic leukemia

  Genomics of drug sensitivity in acute lymphoblastic leukemia

  Study EGAS00001006336

• OAC WGS

  Please see our related publication, 'Molecular profiling to predict immunochemotherapy outcomes in esophageal adenocarcinoma'

  Study EGAS00001006470

• National Cancer Institute Multi-Ancestry Genome-Wide Association Study of Kidney Cancer (NCI-3)

  The National Cancer Institute (NCI) multi-ancestral genome-wide association study (GWAS) of kidney cancer ("NCI-3") was performed by NCI to further investigate common genetic variants associated with risk of kidney cancer and its two major subtypes across individuals of different ancestries (European, African, East Asian, Latin American). The NCI-3 GWAS includes 12,315 cases and 73,091 controls from 25 centers in North America, South America and Europe, genotyped using the Illumina Global Screening Array v2.0. SNP-level results from this GWAS were combined by meta-analysis with results from two earlier NCI European-ancestry GWAS (RCC; phs000351: 1,311 cases and 3,424 controls and phs001736: 2,417 cases and 4,391 controls), a NCI GWAS of African Americans (phs000863; 255 cases and 375 controls), GWAS conducted at other institutions [International Agency for Research on Cancer (scan 1: 2,438 cases and 5,071 controls; scan 2: 2,781 cases and 2,940 controls), The University of Texas MD Anderson Cancer Center (scan 1: 893 cases and 556 controls, scan 2: 1,241 cases and 1,712 controls) and the Institute for Cancer Research, UK (944 cases and 4,024 controls)] and GWAS analyses of data from three large biobanks (Biobank Japan: 523 cases and 86,306 controls; FinnGen: 2,095 cases and 304,956 controls; UK Biobank: 1,807 cases and 348,824 controls). Only individual-level data from NCI-3 and the two MD Anderson Cancer Center scans are included in this dbGaP submission. All study-specific and meta-analysis summary statistics are included.

  Study phs003505

• Field Studies of Human Immunity to Amebiasis in Bangladesh (NIH Birth Cohort) and Exploration of the Biologic Basis for Underperformance of Oral Polio and Rotavirus Vaccines in Bangladesh (PROVIDE)

  NIH birth cohort study Amebiasis is a common cause of diarrhea and is associated with malnutrition in grade-school aged children in an urban slum of Dhaka, Bangladesh. Field Studies of Human Immunity to Amebiasis in Bangladesh was designed to determine the contribution of amebiasis to illness in the first 2 years of life when most deaths due to diarrhea occur, and understand the immunologic and genetic factors that protect children from amebiasis. The hypothesis underlying the study is that susceptibility to amebiasis is determined by host innate and acquired immune responses that vary between individuals in part due to: human genetic polymorphisms; environmental influences including malnutrition and concurrent geohelminth infection; and virulence differences among Entamoeba histolytica genotypes. Specific aims proposed in the design of the study were to: a) Measure the incidence of amebiasis and correlate it with human and parasite genetic polymorphisms, immune responses, and environmental factors such as geohelminth infection and malnutrition; b) Test the hypothesis that protective immunity is mediated both by innate immune responses initiated via TLR stimulation as well as by mucosal IgA against the Gal/GalNAc lectin and systemic IFN-γ; c) Test for the association of common genetic polymorphisms in host innate and acquired immune genes with incidence of amebiasis. 629 newborn babies were enrolled and followed regularly through bi-weekly surveillance for diarrheal episodes, anthropometry at 3-month interval until 60 months of age. The infants that were consented for GWAS analysis were genotyped in 3 separate batches at different times, on 3 different arrays. Quality control was performed on the 3 separate data sets and then jointly after merging. Genetic data available on 447 infants together with their phenotype data is made available in this submission PROVIDE (Performance of Rotavirus and Oral Polio Vaccines in Developing Countries) Study Oral polio and rotavirus vaccines are significantly less effective in children living in the developing world. Environmental enteropathy, which is associated with intestinal inflammation, decreased absorption and increased permeability, may contribute substantially to oral vaccine failure in developing country settings. The primary objective of the study was to determine the association of environmental enteropathy with the efficacy of oral polio and rotavirus vaccines in children in Bangladesh. Secondary and exploratory objectives were designed to address other possible causes of oral vaccine underperformance including malnutrition, interference with maternal or breastmilk antibodies, changes in gut microbiota, and genetic susceptibility. The PROVIDE study was structured as a 2x2 clinical trial with a prospective birth cohort enrollment of 700 infants and their mothers in the urban slum of Mirpur, Dhaka, Bangladesh. All children received the full series of Bangladesh's Expanded Program on Immunization vaccines, including oral polio vaccine (OPV) and followed for their first 2 years of life. Half the children were randomized to receive an inactivated polio vaccine (IPV) for their 4th dose at 39 weeks instead of the standard OPV dose. In the other trial, half the infants received the 2-dose rotavirus vaccine (Rotarix) with delayed dosing at 10 and 17 weeks of age. A detailed description of the study design and procedures can be obtained from PROVIDE methods publication: Kirkpatrick B.D., Colgate R.E., Mychaleckyj J.C., Haque R., Dorothy D.M., Carmolli M.P., et al. (2015) Am J Trop Med Hyg 92, 744-751 The Poliovirus trial and results are described in Mychaleckyj et al, Vaccine 2016 The Rotavirus trial and results are described in Colgate et al, Clin Infect Dis 2016 The PROVIDE infants were genotyped on a custom Affymetrix Axiom array (30K SNPs) at the University of Virginia Center for Public Health Genomics; and on a pre-production version of the Illumina MEGA v2 chip at the Wellcome Trust Sanger Institute, UK. The latter genotyping was performed under the auspices of the VaccGene Consortium. Analyses are ongoing to identify variants associated with the included phenotypes. A manuscript describing the genotyping methods and analysis is in preparation for the initial phenotypes. The Infection Malnutrition Bangladesh Cohort is utilized in the following dbGaP sub-studies. To view genotypes, other molecular data, and derived variables collected in these sub-studies, please click on the following sub-studies below or in the "Sub-studies" box located on the right hand side of this top-level study page phs001475 Infection Malnutrition Bangladesh Cohort. phs001476 Amebiasis Immunity phs001478 Polio Rotavirus Vaccines phs001665 Cryptosporidiosis Enteropathogens

  Study phs001475

• Kenya_GWAS-2.5M_b37

  Genome-wide study of resistance to severe malaria in eleven worldwide populations:Kenya

  Dataset EGAD00010000904

• Malawi_GWAS-2.5M_b37

  Genome-wide study of resistance to severe malaria in eleven worldwide populations:Malawi

  Dataset EGAD00010000903

• Gambia_GWAS-2.5M_b37

  Genome-wide study of resistance to severe malaria in eleven worldwide populations:Gambia

  Dataset EGAD00010000902

• cfDNA methylation dataset for colon cancer

  Enzymatic conversion-based methylation sequencing data (EM-seq) for colon cancer used in the MESA study

  Dataset EGAD50000000075

• Transcriptome sequencing of FFPE and patient-derived cultures

  Transcriptome sequencing of FFPE and patient-derived cultures from clinical study NCT03860376

  Dataset EGAD50000000246

• resistance mechanims to targeted therapies from RNA sequencing

  WTS of tumor tissue biopsies collected at resistance to molecular targeted agents

  Study EGAS50000000487